Reddit Posts
ANVS tiny float (5m) 30% insider ownership received big news today. Gap fill to $100
ANVS stage 3 trial for Parkinsons medicine given FDA go ahead
Annovis Bio ($ANVS) - Supplementary Due Dilligence (with a Powerpoint deck)
$ANVS - Amazing Alzheimer's & Parkinson's disease drug candidate, ULTRA-LOW FLOAT, injustly short & distort of amazing science backed by numerous scientific papers, high insider ownership with diamond grip, multiple catalysts coming for 2022
So Alzheimer stocks are literally dying??
$SAVA released their 9-month clinical study data yesterday, and it's good news. Reaction kinda got buried in the fallout from $ANVS
What's happening to the Alzheimer's stock $ANVS?
My Top Biotech Plays to get your Account Positive by the Years End
ANVS and Alzheimer's--Let's take it to the moon!
Alzheimer plays - $AVXL$ANVS $SAVA $PRTA $BIIB $LLY $ATHA
$SNPX - Phase 2 Alzheimer's stock that just started trading on the Nasdaq - Undervalued
$ANVS play off of $BIIB could go through the roof with their 4.7 million share float
After $AMC, if you want to put your money into something that would change the world and increase the size of your wallet, take a look at $ANVS. Below is a video from the CEO today taking about the cure for Alzheimer's and Parkinson's disease with this new drug in trials. She is changing the world!
ANVS data coming next week. 7x potential. CEO very positive. Just watch the video and you will understand
Mentions
The last bio stock I went in on was ANVS and brother it’s like Hotel California
Sorry, we are in such different worlds on almost everything you said. I don’t invest in a company to dabble. I do my diligence and then I make a significant investment. I don’t invest in biotech stocks to mitigate losses. Risk management is what my index funds are for. I certainly don’t do that in extremely binary companies like this - where the stock goes crazy or goes to zero. My question is a due diligence question. What makes this company so much more compelling than a BIVI or SAVA or ANVS or a whole list of others that have failed despite tantalizing data in early-to-mid stage companies? And as I look more carefully at the data now, what makes us think the effect will be durable? The DLB actually looks very good - but is it durable? However, as I do my due diligence, honestly just on the DLB data this company is wildly under-valued. It’s a shame they are pushing Alzheimer’s ahead of that, where the data is less convincing.
Wait till this guy hears about ANVS
$ANVS over 3 today? Let’s see 👀
Any guesses where ANVS goes after AAIC?
Any chance ANVS will announce something new at AAIC?
IF you’re open to biotech, ANVS is worth looking at. They’re in phase 3 for Alzheimer’s and will be going to phase 3 for Parkinson’s once they raise the funds to pay for it. It’s a heavily shorted stock that had taken a beating despite very promising data. Large insider positions with averages well above current price. Again, biotech is not for everyone. It is a risk with big upside potential in the future.
Thoughts on likelihood of success for ANVS? And no IXHL for July?
ANVS pumping I should have tripled down my cost basis is still 6.5 😂💀
So you’re expecting space travels for ANVS this week?
I just did a quick read and the two (ANVS & AVXL) are different in target molecules and mode of action. ANVS is effectively an mRNA inhibitor. go to wiki to learn about Blacarmesine. My own view is the mitochondria play a substantial role in PD. Hopefully we will one day see a pinch of Blacarmesine added to Buntanetap in a trial.
Just give up on BIO-tech. You’re so much better of literally sports betting. Only way to reliably trade bio-tech is to day trade or swing. ANVS has been “on the come up” for years now. Please give it up, day trading options is far less risky with much higher upside potential.
After careful research, I’m heavy in on ANVS, bought 10k shares
Anyone here in ANVS? I’m seeing all kinds of buy recommendations but it’s just tanking. I’m going long on this. Phase 3 trials for AD butanetap.
ANVS! Alzheimer's and Parkinson's
My high risk/high reward play is ANVS. I think they have the best shot on goal for cracking the Alzheimer’s code as someone who’s been in the industry for a while. This stock will either go to $0 or $1500. Phase 3 AD starts recruiting in January 2025 and results for symptomatic usage will be out after ~6 months. Cassava’s science never made sense to me but I love what I see with Annovis.
Heard some folks talking about ANVS and it went up quite a bit after that and then of course dumped.
Anyone have any holdings in ANVS? Seems promising
ANVS Best shot at halting Alzheimer’s imo
All of my homies are buying ANVS
ANVS is going to make me a multi-millionaire
SAVA doesn't have any placebo-controlled data that says their drug works. If you like the risk/reward of SAVA, check out the various other biotechs with better data and lower market caps (e.g., ANVS, AVXL...).
ANVS their buenetap for Alzheimer’s
Mine is ANVS. It's an Alzheimer's and Parkinson's disease treatment biotech company (tho they have more in their pipeline.) Waiting on partnership, NDA, and/or buyout before a phase 3a for Alzheimer's and a phase 3b for Parking.
ANVS Cost basis is $13 so I’m not being completely crushed by it but I like the science and I’m going to hold until either buyout or bankruptcy. 4000 shares strong 💪🏻
ANVS working on Parkinson's and Alzheimer's. Finished a phase 2/3 study in Alz and phase 3a for Parkinson's. One pill to combat them all, Buntanetap. Their results show the drug works very well against early stage symptoms. The results are revolutionary. They have zillions of patents and more in their pipeline. It's not $$$$$$$ because they're low on funding. Some critics argued the studies were "ad hoc". 🤷♂️🙄 It's a low float stock and only has 11.2 million shares float. They are meeting with the FDA in Sept and Oct to see about an New Drug designation and they are looking for a partnership. If/when they get bought out it's looking at a share price, at least of $80 ($1 billion). Do your own DD! Not investment advice!
ANVS Though I would also invest in any other Alzheimer’s meds that were showing success.
Completely agree and have been a long term ANVS holder. Plus chance they get FDA approval this fall for symptomatic PD while other trials continue.
ANVS is the better neurodegenerative play. Buntenetap inhibits four separate neurotoxic proteins from aggregating in the brain altogether. No ARIA, brain-bleed, or side effects. They just received a new patent for their molecule so the IP is safe for 20 years. Even if they never get approval for the Alzheimer's indication, they're candidate has potential to be a blockbuster for Parkinson's.
Things like understanding the unmet need for the drug (I.E. the FDA will generally be more lenient when approving treatments for Frederick's Ataxia or ALS than something like Diabetes, of which there are already a lot of options), is the compound patentable, how was the trial set up, how are the trial results being analyzed, did only a subset of the trial participants see an effect and if so how will that sway the FDA advisory panel, etc. To give an example, ANVS is a company I am currently invested in for their Parkinson's drug. Their clinical trial only met endpoints for a subset of the sample population which has scared investors but if you understand Parkinson's and understand why the treatment was not impactful on a certain population, the readout makes sense, and due to the unmet need for Parkinson's patients, and the safety profile of the drug, I am fairly confident the stock is undervalued and the drug will get approved. Approval does not translate into sales, but in this case I think the data is compelling enough for patients to consider it as an option. If you're wondering what is weird about the read-out for that drug, the drug was most effective with patients that had been diagnosed with Parkinson's for greater than 3 years, and less impactful with freshly diagnosed patients, which to me makes sense because it's a neurodegenerative disease that worsens over time and a person that was newly diagnosed may or may not even be having symptoms that impact their daily life like someone who has been dealing with it for a long time. It may be harder for them to perform tasks at the beginning compared to a healthy person but it hasn't hit the point where they are reliant on a caretaker.
ANVS and RDDT are my two speculative plays
$ANVS August 16 $10 put 🪦
$ANVS July 19 $10 put ❌
$ANVS July 19 $10 puts 🪦
$ANVS July 19 $10 put 🪦
$ANVS July 19 $10 puts 🪦
# July 2nd - [Squeeze Play Live](http://squeezeplay.live) Alerts Summary $VLCN 5.11$: 07:03 EST Chart↗ - Price: +10.73% | Vol: +800% Squeezed last week. Price back to pre-squeeze level. Low flow + high short% + high borrow fee. $MMV 0.65$: 10:01 EST Chart↗ - Price: +12.76% | Vol: +1781.03% Squeezed last month. Increased after previous support. Low float + high increase in short%. $ZAPP 2.56$: 10:18 EST Fluctuation ↑ - Price: +35.79% | AVG Vol↑: +412.83% Low float + high/increase in short% + high borrow fee. Can it squeeze back to 5$? $SYT 2.70$: 11:10 EST Fluctuation ↑ - Price: +43.69% | AVG Vol↑: +54984.44% Low float + decent borrow fee. Recent positive news. $ANVS 5.68$: 11:53 EST Chart↗ - Price: +8.16% | Vol: +535.80% Almost doubled after the alert to 11$ on positive news. Low float + high short% + high borrow fee. $LGVN 1.77$: 12:47 EST Chart↗ - Price: +14.01% | Vol: -6.39% Low float + high/increase in short% + high borrow fee. Squeezed last month. Increased again after hitting support. $CTNT 0.59$: 15:54 EST Fluctuation ↑ - Price: +31.89% | AVG Vol↑: +305.16% Trend reversal over last week. High increase in short% + high borrow fee. Maybe going back to 1$? $VVPR 2.00$: 17:14 EST Fluctuation ↑ - Price: +34.67% | AVG Vol↑: +516.73% Increased post-market on positive news. Low float + high borrow fee. Resistance at 3$.
ANVS, lock it in people
I am focusing on $ANVS
$ANVS July 19 $10 puts
$ANVS July 19 $5 puts 🚨
$ANVS July 19 $5 puts ❌
Today is a good day to hold $ADAP and $ANVS
So $ADAP had a good day yesterday looking forward to it continuing till PDUFA $ANVS Parkinsons trial readout confirmed on July 2nd $ALT buyout has to be close for them to internally promote a 36 yo to CFO after he passed away.
$ANVS - Parkinsons Disease readout this week. Hoping to see a pump, has a potential for a short squeeze.
Take a look at ANVS July $5 put. High premium for the risk. I’ve sold both June $5 puts expiring tomorrow as well as July puts at same strike.
Anyone still in $ANVS? Investor meeting today at 2PM - hopefully they can find cash very soon
Bought a tiny bit of ANVS hoping to see it go up today AH
$ANVS - Conference call on the stroke of AH. Let’s see what happens
Sold too early on $GERN and $HUMA - still made a decent profit on each. $ANVS - tomorrow conference meeting, hopefully an update on their Buntanetap trial for Parkinson Disease. Readout should be within this month. Saw a job posting for a Senior Clinical Scientist posted two days ago. Looking extremely bullish. Hopefully tomorrow we can see a big green candle AH to push us back to the $12 and $13
Your post with title "BNOX or ANVS?" has been automatically removed from r/PennyStocks for being low-effort/spam. (Low word count) probably by u/automod *I am a bot, and this action was performed automatically. Please [contact the moderators of this subreddit](/message/compose/?to=/r/pennystocks) if you have any questions or concerns.*
$AUTL - Follow-up Data for Phase 2 study released and looking good. Holding for PDUFA later this year $ADAP - Collaboration agreement last week, stock waiting for PDUFA - good cash position from last ER $ANVS - Data readout for June for drug for Parkinsons Disease. Stock loves to run. Lots of insiders holding. $ALT - It’s ALT, down, will probably bounce back up.
Any takers...fockers? This past Friday the US senate passed the National Plan to End Parkinsons Act. Sending it to the White House for President Joe Biden to sign into law. This is great news for Annovis (ANVS) whom plans to release top line Phase 3 Trial data for Parkinsons disease in the next few days.
$ANVS - Data readout for drug in June (Huge position here really expecting a rally soon) $AUTL - PDUFA $ALT - Near support zone, less risky, expecting news very soon (also actual BO potential) $ADAP - PDUFA $XBI should be recovering now, took a dive last week.
Sold $CRKN and $GWAV Bought $AUTL - good ER report + PDUFA hoping for it to reach to $6 or $7 Strengthened my position in $ADAP Still holding $ANVS and $CTXR for their drug trial data readouts next month $CETX - Hail Mary play.
Anavex (AVXL) is highly likely the most promising late-stage Alzheimer’s potential, over ANVS and SAVA. The company completed and succeeded in passing a phase 2b/3 pivotal Alzheimer’s trial in late 2022. The drug is likely to result in halted disease progression or improvement in a large percentage of the patient population (80%+) based on extensive responder/genomic analysis conducted by the company. It’s also SAFE, orally taken, and inexpensive. The company is currently in late stages for filing for approval in Europe, a customer-base that hasn’t seen a new Alzheimer’s drug in decades. The EMA requested the company file based on private conversations and will likely beat any monoclonal antibody to market in Europe. Remember: efficacious, safe, wide-patient applicability, massive market, exclusivity in Europe, and orally taken. FDA is expected to be pursued with a similar copy-paste filing shortly after.
$ANVS - Misguided trial saw the stock tank 70% but it is recovering very nicely - new data to be released in June. $HOLO - Hoping to rinse the shorts (I bought warrants), hoping for that skyrocket $GERN - PDUFA next month $ADAP - PDUFA upcoming $CTXR - within next 45 days Mino-Lok data will be released also has a PDUFA for another drug later this year
Anyone cares to help Maria with her stint to heal Parkinson's from this world? ANVS
$ANVS breaking out, I can see it going to $7.5 very soon and higher
Was in $HUMA, but sold yesterday, looking for a dip back to low 4s. Currently have positions in: $ADAP - PDUFA $ANVS - Trial readout was not as expected, but promising results in certain indications. $CTXR - PDUFA $GERN - PDUFA I love PDUFAs lol
On the sold leg in this case. As an example I'm currently in the following spread on ANVS: 5/17 5p write 5/17 2.5p buy Entered with a $103 credit / $147 risk when the stock was just above $10 now it's $17.50. I'm considering closing the short put on Monday and rolling up to the 7.50 for either 5/17 or 6/21. Both with the initial trade and the roll I'm more than 50% OTM.
ANVS moooning something is brewing
$ANVS....calls look deliciously delicious!!!!!!!!!!!!!! 
$ANVS....calls look deliciously delicious!!!!!!!!!!!!!!
I blew a $250k account on naked calls so now I'll only do call spreads or covered calls. I'll do spreads on the same tickers I've sold puts on or others if it makes sense. IBRX doesn't qualify because going 100% OTM (to match the 50% on the put side) would only give me $0.16 credit spread with ROR of 6.84%. ANVS has a similar problem plus the bid/ask is brutal.
Thanks yes that helps a lot. So if you sold the 180 put when AAPL was at 199 that's only 10% OTM. I don't like being that close to the money on individual stocks. I understand the common advice to only sell puts on stocks you like but your situation illustrates what can happen, having to sell too close to the money to get a decent return on risk, then getting assigned at undesirable prices and having to tie up a lot of BP waiting for them to come back. Personally I prefer selling CSPs and credit spreads on low dollar high IV stocks. I target 30-60DTE \~50% OTM with a 20%+ return on risk, knowing that comes with its own risk, the chance that some of those stocks could go to zero if I get assigned. Couple of examples I'm in right now: IBRX Short May 17 3.00 Put at $0.50 credit ANVS Short May 17 5.00 Put / Long May 17 2.50 Put at $1.03 credit
ANVS Parkinson's and Alzheimer's treatment. It's going to .30 or $300. With my luck, probably .30.
suprised you guys didnt get on $ANVS at least just for the ticker.
What's up with $ANVS....look at April 19 calls....
ANVS for some quick gains…. $$$ will skyrocket by end of this week once the positive news is out!
No ANVS just posted good results from phase 3 Alzheimer’s study and has taken off!
$ANVS. There’s a lot of red flags with this one which have suppressed the stock price. On closer analysis, they are a lot less red than they appear at first glance, and the chance of success in the upcoming P3 trials is not priced in.
$ANVS, P3 PD and AD in January/March 2024, currently at all time lows. Thank me afterwards.
ANVS!!!! OMG, Starting a position today or Monday would be amazing. My average is 16$. Phase 3 Parkinson's TDL is due in December ish Phase 2b Alzheimer's is due in March ish with (hopefully) moving to Phase 3 Alzheimer's after that. 40 billion dollar MC. Low float stock with only like 9 million total shares. High risk but VERY high reward.